Kimberley S Mak, Molly Scannell Bryan, James J Dignam, William U Shipley, Yue Lin, Christopher A Peters, Elizabeth M Gore, Seth A Rosenthal, Kenneth L Zeitzer, David P D'Souza, Eric M Horwitz, Thomas M Pisansky, Jordan M Maier, Susan M Chafe, Tyler P Robin, Mack Roach, Phuoc T Tran, Luis Souhami, Jeff M Michalski, Alan C Hartford, Felix Y Feng, Howard M Sandler, Jason A Efstathiou
BACKGROUND: Androgen deprivation therapy (ADT) has been associated with coronary heart disease and myocardial infarction (MI) in prostate cancer patients, but controversy persists regarding its effects on cardiovascular mortality (CVM). OBJECTIVE: We assessed the long-term relationship between ADT and CVM in a prostate cancer randomized trial (NRG Oncology/Radiation Therapy Oncology Group 9202). DESIGN, SETTING, AND PARTICIPANTS: From 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c-T4, prostate-specific antigen <150 ng/ml) received radiotherapy with 4 mo (short-term [STADT]) versus 28 mo (longer-term [LTADT]) of ADT...
February 1, 2024: European Urology Focus